Current File : /var/www/html/digiprint/public/site/t4zy77w0/cache/f5ea564ce97bd29b8791f249c5a76db6
a:5:{s:8:"template";s:7286:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Lato%3A300%2C400%7CMerriweather%3A400%2C700&ver=5.4" id="siteorigin-google-web-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,header,nav{display:block}a{background-color:transparent}svg:not(:root){overflow:hidden}button{color:inherit;font:inherit;margin:0}button{overflow:visible}button{text-transform:none}button{-webkit-appearance:button;cursor:pointer}button::-moz-focus-inner{border:0;padding:0}html{font-size:93.75%}body,button{color:#626262;font-family:Merriweather,serif;font-size:15px;font-size:1em;-webkit-font-smoothing:subpixel-antialiased;-moz-osx-font-smoothing:auto;font-weight:400;line-height:1.8666}.site-content{-ms-word-wrap:break-word;word-wrap:break-word}html{box-sizing:border-box}*,:after,:before{box-sizing:inherit}body{background:#fff}ul{margin:0 0 2.25em 2.4em;padding:0}ul li{padding-bottom:.2em}ul{list-style:disc}button{background:#fff;border:2px solid;border-color:#ebebeb;border-radius:0;color:#2d2d2d;font-family:Lato,sans-serif;font-size:13.8656px;font-size:.8666rem;line-height:1;letter-spacing:1.5px;outline-style:none;padding:1em 1.923em;transition:.3s;text-decoration:none;text-transform:uppercase}button:hover{background:#fff;border-color:#24c48a;color:#24c48a}button:active,button:focus{border-color:#24c48a;color:#24c48a}a{color:#24c48a;text-decoration:none}a:focus,a:hover{color:#00a76a}a:active,a:hover{outline:0}.main-navigation{align-items:center;display:flex;line-height:1}.main-navigation:after{clear:both;content:"";display:table}.main-navigation>div{display:inline-block}.main-navigation>div ul{list-style:none;margin:0;padding-left:0}.main-navigation>div li{float:left;padding:0 45px 0 0;position:relative}.main-navigation>div li:last-child{padding-right:0}.main-navigation>div li a{text-transform:uppercase;color:#626262;font-family:Lato,sans-serif;font-size:.8rem;letter-spacing:1px;padding:15px;margin:-15px}.main-navigation>div li:hover>a{color:#2d2d2d}.main-navigation>div a{display:block;text-decoration:none}.main-navigation>div ul{display:none}.menu-toggle{display:block;border:0;background:0 0;line-height:60px;outline:0;padding:0}.menu-toggle .svg-icon-menu{vertical-align:middle;width:22px}.menu-toggle .svg-icon-menu path{fill:#626262}#mobile-navigation{left:0;position:absolute;text-align:left;top:61px;width:100%;z-index:10}.site-content:after:after,.site-content:before:after,.site-footer:after:after,.site-footer:before:after,.site-header:after:after,.site-header:before:after{clear:both;content:"";display:table}.site-content:after,.site-footer:after,.site-header:after{clear:both}.container{margin:0 auto;max-width:1190px;padding:0 25px;position:relative;width:100%}@media (max-width:480px){.container{padding:0 15px}}.site-content:after{clear:both;content:"";display:table}#masthead{border-bottom:1px solid #ebebeb;margin-bottom:80px}.header-design-2 #masthead{border-bottom:none}#masthead .sticky-bar{background:#fff;position:relative;z-index:101}#masthead .sticky-bar:after{clear:both;content:"";display:table}.sticky-menu:not(.sticky-bar-out) #masthead .sticky-bar{position:relative;top:auto}#masthead .top-bar{background:#fff;border-bottom:1px solid #ebebeb;position:relative;z-index:9999}#masthead .top-bar:after{clear:both;content:"";display:table}.header-design-2 #masthead .top-bar{border-top:1px solid #ebebeb}#masthead .top-bar>.container{align-items:center;display:flex;height:60px;justify-content:space-between}#masthead .site-branding{padding:60px 0;text-align:center}#masthead .site-branding a{display:inline-block}#colophon{clear:both;margin-top:80px;width:100%}#colophon .site-info{border-top:1px solid #ebebeb;color:#626262;font-size:13.8656px;font-size:.8666rem;padding:45px 0;text-align:center}@media (max-width:480px){#colophon .site-info{word-break:break-all}}@font-face{font-family:Lato;font-style:normal;font-weight:300;src:local('Lato Light'),local('Lato-Light'),url(http://fonts.gstatic.com/s/lato/v16/S6u9w4BMUTPHh7USSwiPHA.ttf) format('truetype')}@font-face{font-family:Lato;font-style:normal;font-weight:400;src:local('Lato Regular'),local('Lato-Regular'),url(http://fonts.gstatic.com/s/lato/v16/S6uyw4BMUTPHjx4wWw.ttf) format('truetype')}@font-face{font-family:Merriweather;font-style:normal;font-weight:400;src:local('Merriweather Regular'),local('Merriweather-Regular'),url(http://fonts.gstatic.com/s/merriweather/v21/u-440qyriQwlOrhSvowK_l5-fCZJ.ttf) format('truetype')}@font-face{font-family:Merriweather;font-style:normal;font-weight:700;src:local('Merriweather Bold'),local('Merriweather-Bold'),url(http://fonts.gstatic.com/s/merriweather/v21/u-4n0qyriQwlOrhSvowK_l52xwNZWMf_.ttf) format('truetype')} </style>
</head>
<body class="cookies-not-set css3-animations hfeed header-design-2 no-js page-layout-default page-layout-hide-masthead page-layout-hide-footer-widgets sticky-menu sidebar wc-columns-3">
<div class="hfeed site" id="page">
<header class="site-header" id="masthead">
<div class="container">
<div class="site-branding">
<a href="#" rel="home">
{{ keyword }}</a> </div>
</div>
<div class="top-bar sticky-bar sticky-menu">
<div class="container">
<nav class="main-navigation" id="site-navigation" role="navigation">
<button aria-controls="primary-menu" aria-expanded="false" class="menu-toggle" id="mobile-menu-button"> <svg class="svg-icon-menu" height="32" version="1.1" viewbox="0 0 27 32" width="27" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<path d="M27.429 24v2.286q0 0.464-0.339 0.804t-0.804 0.339h-25.143q-0.464 0-0.804-0.339t-0.339-0.804v-2.286q0-0.464 0.339-0.804t0.804-0.339h25.143q0.464 0 0.804 0.339t0.339 0.804zM27.429 14.857v2.286q0 0.464-0.339 0.804t-0.804 0.339h-25.143q-0.464 0-0.804-0.339t-0.339-0.804v-2.286q0-0.464 0.339-0.804t0.804-0.339h25.143q0.464 0 0.804 0.339t0.339 0.804zM27.429 5.714v2.286q0 0.464-0.339 0.804t-0.804 0.339h-25.143q-0.464 0-0.804-0.339t-0.339-0.804v-2.286q0-0.464 0.339-0.804t0.804-0.339h25.143q0.464 0 0.804 0.339t0.339 0.804z"></path>
</svg>
</button>
<div class="menu-menu-1-container"><ul class="menu" id="primary-menu"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-20" id="menu-item-20"><a href="#">About</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-165" id="menu-item-165"><a href="#">Blog</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-24" id="menu-item-24"><a href="#">FAQ</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-22" id="menu-item-22"><a href="#">Contacts</a></li>
</ul></div> </nav>
<div id="mobile-navigation"></div>
</div>
</div>
</header>
<div class="site-content" id="content">
<div class="container">
{{ text }}
<br>
{{ links }}
</div>
</div>
<footer class="site-footer " id="colophon">
<div class="container">
</div>
<div class="site-info">
<div class="container">
{{ keyword }} 2021</div>
</div>
</footer>
</div>
</body>
</html>";s:4:"text";s:15263:"About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics … Brainstorm Cell Therapeutics, Inc. Dividend policy None Price as of: MAY 17, 06:23 AM EDT $3.35 -0.03 -0.89% Watchlist Overview. View today's stock price, news and analysis for Brainstorm Cell Therapeutics Inc. (BCLI). BrainStorm Cell Therapeutics received a $495,330 grant from the National Multiple Sclerosis (MS) Society to support biomarker studies in its … 07:21 AM ET The study achieved the primary endpoint of safety and improvements were observed in secondary endpoints spanning neurologic function, cognition, and … Autistic Disorder is a broad term used to describe a group of neurodevelopmental disorders.These disorders are characterized by problems with communication and social interaction.People with ASD often demonstrate restricted, repetitive, and stereotyped interests or patterns of behavior. Our data shows that Abbhi Capital is the largest shareholder with 6.1% of shares outstanding. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics … Jun 23, 2020 5:45 AM EDT. BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update. The firm owned 16,050 shares of the biotechnology company’s stock after selling 18,100 shares during the quarter. Institutional investors purchased a net $603.5 thousand shares of BCLI during the quarter ended March 2019. Risk Analysis. Share your opinion and gain insight from other stock traders and investors. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. Autistic Disorder is a broad term used to describe a group of neurodevelopmental disorders.These disorders are characterized by problems with communication and social interaction.People with ASD often demonstrate restricted, repetitive, and stereotyped interests or patterns of behavior. The most recent transaction is an insider purchase by Setboun David, the company’s EVP and COO. Brainstorm Cell (BCLI) Recent Earnings. The Brainstorm Cell Therapeutics Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. Brainstorm Cell Therapeutics Inc is a developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. Earnings are forecast to grow 58.59% per year. BrainStorm to Present at the Raymond James Human Health Innovations Conference Tuesday, 9 June 2020 yahoo. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics, Inc. to Host Earnings Call. New. At the close, Brainstorm Cell’s trading volume reached 37.2K shares. Brainstorm Cell Therapeutics | 2.717 follower su LinkedIn. Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. If you have previously registered, please log in below: First Name * Last Name Last Name * Company BrainStorm Cell Therapeutics Inc. is a biotechnology company. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was in 3 hedge funds’ portfolios at the end of September. Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. 4/19/2021. According to TipRanks.com, McCarthy is a top 100 analyst with an average return of 51.1% and a 54.3% success rate. BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index Thursday, 11 June 2020 prnewswire. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. We would like to show you a description here but the site won’t allow us. Chaim Lebovits - … Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. Brainstorm Cell Therapeutics Inc. NASDAQ Updated May 21, 2021 11:55 PM BCLI 3.51 0.02 (0.57%). BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. View the latest Brainstorm Cell Therapeutics Inc. (BCLI) stock price, news, historical charts, analyst ratings and financial information from WSJ. The BrainStorm treatment regimen consists of a person’s own stem cells (called autologous) being removed from bone marrow and then grown outside of the body in the presence of a chemical owned by the company called NurOwn, which aims to increase the stem cells’ ability to make and secrete protective substances called growth factors. More Details. Brainstorm Cell Therapeutics stock price target raised to $20 from $9 at Maxim Group MarketWatch. Brainstorm downgraded to neutral from buy at Dawson James Securities MarketWatch. At CIRM, we are funding two clinical trials run by Cedars-Sinai and BrainStorm Cell Therapeutics testing stem cell-based treatments for ALS. On the other hand, the S&P 500 Index was up 0.36% in the last trading session while the Dow Jones Industrial closed the … Brainstorm Cell Therapeutics has a beta of 0.37, meaning that its … Brainstorm Cell Therapeutics Inc, Hackensack, New Jersey. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The stem cells are then cultured in the lab under conditions that convert them into biological factories secreting a variety of neurotrophic factors that help protect the nerve cells damaged by ALS. It focuses on … The company was founded in 2000 … News & Research. BRAINSTORM CELL THERAPEUTICS LTD is located in PETAH TIKVA, Israel and is part of the Pharmaceutical Manufacturing Industry. He/she will be responsible for the operation of production, maintaining records, and laboratory environment to comply with Good Manufacturing Practices and Standard Operating Procedures. More Details. Brainstorm Cell Therapeutics Inc. has a P/E ratio of 0 against that of Amgen Inc’s 20.76 while Bristol-Myers Squibb Company is showing 0 for the same. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform through an exclusive, worldwide licensing agreement. Compare. If you had invested in Brainstorm Cell Therapeutics stock at $8.25 , your return over the last 17 years would have been -58.18% , for an annualized return of -5% . He/she will be responsible for developing and scaling up cell production processes and operations. Autistic Disorder is a broad term used to describe a group of neurodevelopmental disorders.These disorders are characterized by problems with communication and social interaction.People with ASD often demonstrate restricted, repetitive, and stereotyped interests or patterns of behavior. Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. Post-Market 0.05 (1.43%) PRESS RELEASES. Risk and Volatility. Michael Wood - IR, LifeSci Advisors. While BrainStorm Cell Therapeutics' has other clinical trials underway, the one testing NurOwn as an ALS treatment was the one that had advanced the furthest. Post-Market 0.05 (1.43%) BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update. Brainstorm-Cell Therapeutics: ClinicalTrials.gov Identifier: NCT03799718 Other Study ID Numbers: BCT-101-US : First Posted: January 10, 2019 Key Record Dates: Last Update Posted: November 20, 2020 Last Verified: July 2020 Blackrock Inc. is the largest shareholder of the company, while 115 institutions own stock in it. By PR Newswire. In Clark’s memory and for everyone in the ALS community, we hope these trials one day lead to new treatment options for the 5,000 thousand newly diagnosed cases each year in the U.S. Rewards. Get the latest Brainstorm Cell Therapeutics In (BCLI) stock news and headlines to help you in your trading and investing decisions. Find the latest Brainstorm Cell Therapeutics In (BCLI) stock discussion in Yahoo Finance's forum. The company’s stock price has collected -37.43% of loss in the last five trading sessions. The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates the company’s cell-based therapy NurOwn from mesenchymal stem cells (MSCs).. Brainstorm Cell Therapeutics Inc. (BCLI) is priced at $4.58 after the most recent trading session. BrainStorm Cell Therapeutics – NurOwn Background. Brainstorm Cell Therapeutics reported positive topline data from a phase 2 trial assessing three repeated administrations of NurOwn (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). In depth view into Brainstorm Cell Therapeutics Price including historical data from 2003, charts, stats and industry comps. Brainstorm Cell Therapeutics Inc (Brainstorm Cell Therapeutics Inc is lower by Monday morning, with the stock decreasing -4.42% in pre-market trading to 3.68.BCLI's short-term technical score of 3 indicates that the stock has traded less bullishly over … Maxim Group analyst Jason McCarthy assigned a Buy rating to Brainstorm Cell Therapeutics (BCLI – Research Report) yesterday and set a price target of $12.00.The company’s shares closed last Tuesday at $3.58, close to its 52-week low of $2.97. About Mr. Araya is currently serving as the Chief Commercial Officer for Brainstorm Cell Therapeutics. Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 Risk Analysis. Brainstorm Cell Therapeutics Inc. (BCLI) Insider Activity. Brainstorm Cell Therapeutics Inc. insiders own 17.89% of total outstanding shares while institutional holders control 22.74%, with the float percentage being 27.7%. Earnings are forecast to grow 58.59% per year. Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. Get BrainStorm Therapeutics is using mesenchymal stem cells that are taken from the patient’s own bone marrow. BrainStorm Cell Therapeutics, the company sponsoring this trial, is isolating mesenchymal stem cells from the patient’s own bone marrow. BrainStorm Cell Therapeutics met with U.S. Food and Drug Administration (FDA) officials regarding its plans for a semi-automatic manufacturing process for NurOwn, the company’s investigational cell-based therapy for amyotrophic lateral sclerosis (ALS).. The company has a Forward Dividend ratio of 0, with its dividend yield at 0%. Jan 20, 2021. The author writes: Brainstorm Cell Therapeutics Inc is a biotechnology company. Brainstorm Cell Therapeutics. According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 38.3% and a 48.1% success rate. Home Dividend Stocks Health Care Biotech Pharma Biotech Brainstorm Cell Therapeutics, Inc. (BCLI) BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases. Rewards. What we know now is the fact that Brainstorm Cell Therapeutics reported disappointing results today regarding their late-stage clinical trial involving its experimental stem cell therapy for ALS. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The company report on March 24, 2021 that BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS.. Get the hottest stocks to trade every day before the market opens 100% free. The stock touched a low price of $4.51. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive … The small, open-label clinical … NEW YORK, NY / ACCESSWIRE / February 22, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ:BCLI). Investors who purchased Brainstorm securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: … Brainstorm Cell Therapeutics is based in New York. Brainstorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson’s Disease. The company stated that its phase two study observed improvements in secondary endpoints including diminishing inflammatory mechanisms, promoting repair and neurological functions. Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It … BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a … Brainstorm Cell Therapeutics was expecting to see response rates of 35% for its drug compared to 15% for the placebo. The Company holds the rights to … 11:16 AM ET. These stem cells are then modified in the lab to boost their production of neurotrophic factors, which are known to help support and protect neurons, the cells destroyed by ALS. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. Find real-time BCLI - Brainstorm Cell Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. The Company holds the rights to … A great summary of the facts can be found in this Seeking Alpha article on the subject. Brainstorm Cell Therapeutics | 2,751 followers on LinkedIn. Get Brainstorm Cell Therapeutics Inc historical price data for BCLI stock. At the very opening of the session, the stock price was $4.90 and reached a high price of $5.04, prior to closing the session it reached the value of $6.90. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The investigation concerns whether Brainstorm and certain of its officers and/or directors have … BrainStorm Cell Therapeutics To Join The Russell 2000® Index And Russell 3000® Index. ";s:7:"keyword";s:23:"brainstorm therapeutics";s:5:"links";s:904:"<a href="http://digiprint.coding.al/site/t4zy77w0/bitcoin-time-traveler-2021">Bitcoin Time Traveler 2021</a>,
<a href="http://digiprint.coding.al/site/t4zy77w0/hill-and-ponton-calculator">Hill And Ponton Calculator</a>,
<a href="http://digiprint.coding.al/site/t4zy77w0/imaginary-enemy-levante">Imaginary Enemy Levante</a>,
<a href="http://digiprint.coding.al/site/t4zy77w0/dark-mode-button-animation">Dark Mode Button Animation</a>,
<a href="http://digiprint.coding.al/site/t4zy77w0/plasma-weapons-wikipedia">Plasma Weapons Wikipedia</a>,
<a href="http://digiprint.coding.al/site/t4zy77w0/aishwarya-lekshmi-instagram-picuki">Aishwarya Lekshmi Instagram Picuki</a>,
<a href="http://digiprint.coding.al/site/t4zy77w0/ladies-night-games-for-home">Ladies Night Games For Home</a>,
<a href="http://digiprint.coding.al/site/t4zy77w0/sony-bravia-netflix-surround-sound">Sony Bravia Netflix Surround Sound</a>,
";s:7:"expired";i:-1;}
Mini Shell